New results on alirocumab (Praluent) show that it is safe and effective for patients with familial hypercholesterolemia (FH), and yet these patients are faced with an unprecedented situation where some payers refuse to pay for the therapy, said Jay Edelberg, MD, PhD, vice president and head of Cardiovascular Development and Cardiovascular Affairs at Sanofi.
New results on alirocumab (Praluent) show that it is safe and effective for patients with familial hypercholesterolemia (FH), and yet these patients are faced with an unprecedented situation where some payers refuse to pay for the therapy, said Jay Edelberg, MD, PhD, vice president and head of Cardiovascular Development and Cardiovascular Affairs at Sanofi.
Transcript
What do the results of ODYSSEY ESCAPE tell us about the safety of Praluent for patients with familial hypercholesterolemia?
These results of ODYSSEY ESCAPE really build on our continued knowledge of the safety and efficacy of Praluent for our patients who continue to live with FH. Now, ESCAPE specifically focused on those patients who required apheresis to help remove the cholesterol from their blood. And we’ve seen great results with Praluent being able to actually be both safe and effective for patients with FH, and, in fact, many patients actually probably don’t need as much apheresis when they’re taking Praluent.
Results presented at AHA show that of the patients who stopped taking Praluent, 30% did so because their payer would not pay or stopped paying for the therapy. Is there any precedent for this?
There’s no precedent for what we’re seeing in terms of the difficulty of our patients to be able to get Praluent when they’re prescribed. The appropriate patients for Praluent are those with FH or atherosclerotic cardiovascular disease who need additional [low-density lipoprotein] lowering on top of maximally tolerated statins. Those patients are having a really hard time about getting this when they’re prescribed. That’s really unprecedented.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More